Sector News

Lilly CFO leaves to join Alphabet

June 8, 2024
Life sciences

In making the jump to Alphabet, Ashkenazi is joining one of the few companies larger than Lilly by market value, as the drugmaker’s worth has swelled substantially due to the success of its obesity and diabetes medicines.

But Alphabet brings in significantly more revenue and profit than does Lilly. In the first quarter, Alphabet reported net income of $23.7 billion on revenue of more than $80 billion. Lilly reported net income of $2.2 billion on revenue of about $8.8 billion over the same period.

Google and Alphabet are getting a CFO with a record of “long-term investment to fuel innovation and growth” as the companies navigate the rapid evolution of artificial intelligence, CEO Sundar Pichai said. “I look forward to working with Anat as we invest responsibly to support our next wave of growth,” Pichai said in a statement.

For Lilly, Ashkenazi’s departure adds to a fair bit of turnover in the company’s top leadership. Over the past nine months, the drugmaker has announced the retirement of key executives including the head of its diabetes division, its treasurer, its chief ethics and compliance officer and its executive vice president of global quality.

Lilly said it’s conducting an internal and external search for a new CFO. Ashkenazi will continue to serve on the executive committee as well as maintain her role of CFO through July, Lilly said.

Ashkenazi holds a bachelor’s degree in economics and business administration from Hebrew University and earned her MBA from Tel Aviv University. She will be based in the Bay Area.

By Kristin Jensen


comments closed

Related News

June 16, 2024

Bayer’s biotech head Jens Vogel says good-bye after 4 years

Life sciences

While Vogel didn’t cite any broader organizational changes as the reason behind his resignation, his departure comes amid a heavy-handed restructuring at the German pharma. Back in January, Bayer unveiled plans that have ultimately led to the elimination of more than 1,500 roles in the first three months of 2024.

June 16, 2024

Ventilator maker Vyaire Medical files for bankruptcy

Life sciences

The global ventilation and respiratory device manufacturer—originally spun out as a joint venture between BD and Apax Partners in 2016—said its decision followed “below-plan performance in the first half of the financial year, which frustrated efforts to refinance company debt,” and that Vyaire will remain open for business in the interim.

June 16, 2024

Pfizer, Flagship name first target for multibillion-dollar collaboration: obesity

Life sciences

Pfizer and Flagship Pioneering have settled on the first target for their billion-dollar, multiprogram collaboration, and it’s not exactly a surprise: The New York Big Pharma giant will work with the venture creation firm’s ProFound Therapeutics to develop new obesity drugs.

How can we help you?

We're easy to reach